Identification of caspases that cleave presenilin-1 and presenilin-2 Five presenilin-1 (PS1) mutations do not alter the sensitivity of PS1 to caspases by van de Craen, Marc et al.
Identi¢cation of caspases that cleave presenilin-1 and presenilin-2
Five presenilin-1 (PS1) mutations do not alter the sensitivity of PS1 to caspases
Marc van de Craena, Chris de Jongheb, Ilse van den Brandea, Wim Declercqa,
Geert van Gassenb, Wim van Criekingea, Inge Vanderhoevenb, Walter Fiersa,
Christine van Broeckhovenb, Lydia Hendriksb, Peter Vandenabeelea;*
aDepartment of Molecular Biology, Flanders Interuniversity Institute for Biotechnology and University of Gent, K.L. Ledeganckstraat 35,
B-9000 Ghent, Belgium
bLaboratory of Neurogenetics, Born-Bunge Foundation, Flanders Interuniversity Institute for Biotechnology and University of Antwerpen,
Universiteitsplein 1, B-2610 Wilrijk, Belgium
Received 25 November 1998
Abstract Mutations in the presenilin (PS) genes PS1 and PS2
are involved in Alzheimer’s disease (AD). Recently, apoptosis-
associated cleavage of PS proteins was identified. Here we
demonstrate that PS1 as well as PS2 are substrates for different
members of the caspase protein family. Remarkably, the
caspases acting on PS1 could be subdivided in two groups. One
group, containing caspase-8, -6 and -11, cleaved PS1 after
residues ENDD329 and to a lesser extent after residues
AQRD341. A second group consisting of caspase-3, -7 and -1
acted uniquely on AQRD341. Importantly, these two cleavage
sites were also recognized by caspases in the C-terminal PS1
fragment produced by constitutive proteolysis. In decreasing
order of activity, caspase-8, -3, -1, -6 and -7 proteolysed PS2 at
the recognition site D326SYD329. Caspase-8 and -3 exhibited the
highest proteolytic activity on both PS1 and PS2. PS1 and PS2
were not hydrolyzed by caspase-2 and PS2 also not by caspase-
11. None of five missense mutations affected the sensitivity of
PS1 to caspase-mediated cleavage. This suggests that AD
pathogenesis associated with PS1 missense mutations cannot be
explained by a change in caspase-dependent processing.
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1. Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder of
the central nervous system leading to dementia and ultimately
to death. AD cases usually occur sporadically, although ge-
netic factors play an important role in at least half of the
cases. Three AD genes were identi¢ed causing early-onset
familial AD (age at onset 6 65 year): the amyloid precursor
protein gene [1], the presenilin-1 gene (PS1) [2] and the pre-
senilin-2 gene (PS2) [3,4]. The majority of the mutations are
missense mutations and are found in PS1. In addition, apoli-
poprotein E-4 is a risk factor for AD [5,6].
The PS genes encode two homologous proteins (PS1/PS2)
of approximately 450 amino acids having 67% similarity [2,4].
PS1/PS2 most likely have eight transmembrane domains and
are located in the endoplasmic reticulum, to a lesser extent in
the Golgi apparatus [7^10]. Two di¡erent types of proteolysis
were identi¢ed for PS1/PS2. Constitutional, tightly regulated
proteolysis occurs at and near residue M294 for PS1 by yet
unknown endoproteases [11,12]. Constitutional proteolytic
fragments were also described for PS2 [11^13]. Recently, an
additional apoptosis-related proteolytic pathway was charac-
terized [14,15]. Involvement of PS1/PS2 in apoptosis was ¢rst
suggested by enhanced sensitivity to di¡erent apoptotic stim-
uli when PS2 was overexpressed [16,17] and by reduced sensi-
tivity in the presence of an antisense PS2 construct [16,18]. In
addition, apoptotic stimuli induced caspase-dependent cleav-
age of both PS1 and PS2 [14,15]. Peptide inhibitor studies
strongly suggested that in mouse brain homogenates caspases
other than caspase-3 execute PS1/PS2 cleavage [15]. The en-
hanced capacity of the PS2 (I141N) mutant to induce cell
death [16,19] is accompanied by increased apoptosis-associ-
ated processing of the PS2 (I141N) mutant as compared to
wild-type (wt) PS2 [14]. The e¡ect of caspase-mediated cleav-
age of PS1/PS2 on apoptosis is still under investigation.
Nevertheless, it was demonstrated that the C-terminal PS2
fragment antagonizes the progression of cell death [20], where-
as full-length PS2 could be important for the induction of cell
death [19]. Consequently, cleavage of PS2 may constitute a
negative feedback signal in the pathway to cell death.
Caspases have been shown to be part of the cell death
machinery [21,22]. To date, 10 human and nine murine mem-
bers of the caspase family have been identi¢ed [22^26]. Casp-
ases are cysteine proteases which speci¢cally proteolyse after
Asp residues [27,28]. The exact initiation mechanism of the
caspase activation cascade is still largely unknown but once
caspases are active, they are able to activate other caspases by
cleavage after speci¢c Asp residues. Activation of caspases
¢nally results in the cleavage of speci¢c caspase substrates
[29]. Hence, the cell is prepared to die in a subtle and orches-
trated way, which consists of a disassembly of critical molec-
ular structures, permitting the condemned cell to vanish with
a minimal disruption of surrounding tissues.
In the present study, we demonstrate that PS1 is cleaved by
multiple caspases at two di¡erent sites, whereas PS2 is pro-
teolysed by multiple caspases at one site only, caspase-8 and
caspase-3 being the most potent PS1/PS2-cleaving caspases.
Additionally, we provide evidence that PS1 missense muta-
tions do not alter the sensitivity of PS1 to caspase-mediated
proteolysis.
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2. Materials and methods
2.1. Plasmid constructions
Human PS1/PS2 cDNAs were cloned downstream of the T7 RNA
polymerase promoter in a pSG5 vector (Stratagene Cloning Systems,
La Jolla, CA, USA) to result in pSG-PS1 [30] and pSG-PS2 plasmids,
respectively [30]. Site-directed mutagenesis was applied to introduce
¢ve missense mutations in PS1, viz. Y115C, I143F, I143T, E318G or
G384A (De Jonghe et al., in preparation). PS1 and PS2 caspase cleav-
age site mutants were constructed using a QuickChange site-directed
mutagenesis kit (Stratagene Cloning Systems) according to the man-
ufacturer’s instructions. The two potential cleavage sites ENDD329
and AQRD341 of PS1 were mutated to ENAA and AQRA, respec-
tively. For the ¢rst PS1 mutant (pSG-PS1M1), the primers
TGTTGCAGAGAATGCTGCCGGCGGGTTCAGTGA and TCA-
CTGAACCCGCCGGCAGCATTCTCTGCAACA were used. The
primers GGAAGCCCAGAGGGCTAGCCATCTAGGGCCTC and
GAGGCCCTAGATGGCTAGCCCTCTGGGCTTCC were used
for the second PS1 mutant (pSG-PS1M2). All the PS1 constructs
were devoid of the VRSQ-coding sequence. One potential caspase
cleavage site of PS2, namely D326SYD329, was mutated to GSYA
using the primers GGAGATGGAAGAAGGATCCTATGCTAG-
CTTTGGGGAGCCTT and AAGGCTCCCCAAAGCTAGCATAG-
GATCCTTCTTCCATCTCC.
2.2. In vitro transcription and translation
Coupled in vitro transcription/translation in the presence or absence
of canine microsomal membranes was performed using a rabbit
reticulocyte lysate-based TNT kit from Promega (Madison, WI,
USA) according to the manufacturer’s recommendations. The plas-
mids described above were applied as a template for T7 RNA polym-
erase.
2.3. Caspase cleavage assay
Since autoprocessing of murine caspases in bacteria occurs with
variable e⁄ciency, we chose to estimate the amount of active caspase
in a puri¢ed preparation by computer quanti¢cation of the large sub-
unit (V20 kDa) of mature recombinant caspase (M. Van de Craen,
unpublished results). An amount of puri¢ed murine caspase contain-
ing 60 ng of large subunit (p20) was incubated with 2 Wl of in vitro
radiolabeled substrates in a total volume of 25 Wl of ‘caspase bu¡er’
(50 mM HEPES pH 7.5, 10 mM DTT, 1 mM EDTA, 1 mM PMSF,
50 WM leupeptin and 20 Wg/ml aprotinin) for 1.5 h at 37‡C. The
resulting cleavage products were analyzed on 12.5% SDS-PAGE. In
order to avoid massive aggregation of PS1/PS2, the samples were not
boiled before loading onto SDS-PAGE [31]. The caspase activity re-
corded on Ac-DEVD-AMC peptide caspase substrate (Peptide Insti-
tute, Osaka, Japan) was 11 726 U/mg for caspase-1, 42 000 U/mg for
caspase-2, 8 004 500 U/mg for caspase-3, 568 180 U/mg for caspase-6,
312 800 U/mg for caspase-7, 911 950 U/mg for caspase-8, and 17 969
U/mg for caspase-11. One unit of puri¢ed caspase represents the
amount of enzyme necessary to generate 1 pmol AMC/min from
50 WM Ac-DEVD-AMC tetrapeptide substrate at 30‡C.
3. Results
3.1. PS-1 is proteolysed at two cleavage sites (D329 and D341)
by multiple caspases
In order to test whether puri¢ed caspases are able to pro-
teolyse human PS1, wt PS1 was labeled in vitro with [35S]Met
and incubated with seven di¡erent puri¢ed murine caspases
(caspase-1, -2, -3, -6, -7, -8 or -11) in a ‘caspase bu¡er’. Casp-
ase-11 is considered to be the murine counterpart of human
caspase-4 [24]. Caspase-mediated cleavage of PS1 resulted in
V40-kDa and V13-kDa fragments for caspase-3, -7, -1 and -
6, and in additional V36-kDa and V14.6-kDa fragments for
caspase-8, -6, and -11 (Figs. 1 and 2). Caspase-2 did not
proteolyse PS1. The caspases are mentioned in a decreasing
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Fig. 1. In vitro cleavage of PS1 by puri¢ed caspases. An amount of
murine caspase containing 60 ng of large subunit was incubated in
25 Wl caspase bu¡er with 2 Wl of [35S]Met-labeled human PS1. Reac-
tion products were separated on 12.5% SDS-PAGE and analyzed by
autoradiography. Closed arrowhead, full-length PS1; open arrow-
heads, cleavage products. *, fragments migrating like alternative
cleavage fragments previously observed in vivo [14,15,37,38].
Fig. 2. In vitro cleavage of PS1 by puri¢ed caspases. An amount of murine caspase containing 60 ng of large subunit was incubated in 25 Wl
caspase bu¡er with 2 Wl of [35S]Met-labeled human PS1. Reaction products were separated on 12.5% SDS-PAGE and analyzed by autoradiog-
raphy. Closed arrowhead, full-length PS1; open arrowheads, cleavage products. *, fragments migrating like alternative cleavage fragments previ-
ously observed in vivo [14,15,37,38].
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order of activity on PS1. In mammalian cells, the alternative
PS1 cleavage fragment migrates on SDS-PAGE like a mole-
cule of V14 kDa [14].
It was demonstrated by N-terminal sequencing that the C-
terminal fragment generated under apoptotic conditions is due
to proteolytic cleavage between D341 and S342 [15]. However,
examination of the primary amino acid sequence of PS1 re-
vealed that another potential caspase cleavage site, viz.
ENDD329, is present 12 amino acids N-terminally from
D341. In order to investigate whether both ENDD329 and
AQRD341 sites are targets for caspase-mediated cleavage,
these sites were mutated to ENAA329 (PS1 mutant 1 or
PS1M1) and AQRA341 (PS1 mutant 2 or PS1M2), respec-
tively. Caspase-3 was still able to hydrolyze PS1M1 but not
PS1M2 (Figs. 2 and 3). The same pattern, but less pro-
nounced, was observed with caspase-7 and -1. These results
indicate that caspase-3, -7 and -1 cleaved PS1 at the AQRD341
site (Fig. 1). On the other hand, caspase-8 vigorously proteo-
lysed PS1M2 to the 36-kDa fragment, whereas the 40-kDa
band was absent. As expected, the 36-kDa band was not
produced by the PS1M1 mutant but a weak 40-kDa fragment
was still observed (2). The same pattern, but less pronounced,
was obtained with caspase-6 and -11. These data reveal that
caspase-8, -6 and -11 use both caspase cleavage sites but pre-
fer the ENDD329 site (Fig. 1). The faint 44-kDa band ob-
tained with caspase-6, and to a lesser extent with caspase-8,
is of unknown origin.
As conventional cleavage of PS1 at and near M294 by un-
known proteases results in an N-terminal fragment (PS1-
NTF) and a C-terminal fragment (PS1-CTF) that are predom-
inantly present in brain tissue [11,12,32], it is also important
to examine these fragments for their sensitivity to caspase
cleavage. Fig. 4 shows that PS1-NTF (ranging from amino
acids 1 to 295) was not cleaved by caspase-8 or caspase-3.
However, caspase-8 recognized both caspase cleavage sites
in PS1-CTF (ranging from amino acids 291 to 476), whereas
caspase-3 proteolysed PS1-CTF at one site (Fig. 4).
3.2. PS-2 is proteolysed by several caspases at one site (D329)
Incubation of PS2 with di¡erent concentrations of caspases
showed that PS2, in contrast to PS1, was cleaved at the same
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Fig. 3. Schematic representation of PS1, the mutants PS1M1 and
PS1M2, as well as the predicted cleavage products. Fig. 4. Incubation of caspase-3 or caspase-8 with radiolabeled PS1-
NTF or PS1-CTF fragments. Constitutional cleavage of PS1 at and
near M294 results in an N-terminal fragment (PS1-NTF) and a
C-terminal fragment (PS1-CTF) that are predominantly present in
brain tissue. Caspase-3 as well as caspase-8 were incubated under
standard conditions with radiolabeled PS1-NTF (amino acids 1^295)
or PS1-CTF (amino acids 291^476). Symbols, see Fig. 1.
Fig. 5. In vitro cleavage of PS2 by puri¢ed caspases. An amount of puri¢ed murine caspases was incubated in 25 Wl caspase bu¡er with in vi-
tro transcribed and translated human PS2. Among those caspases that easily cleave PS2, several enzyme concentrations were used. Closed ar-
rowhead, full-length PS2; open arrowheads, cleavage products. *, fragments migrating like alternative cleavage fragments previously observed
in vivo [14,15]. b, bands migrating as theoretically expected (see Fig. 7).
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site(s) by most caspases (Figs. 5 and 7). Using the highest
concentration of caspase-8 (60 ng p20 per 25 Wl), PS2 was
proteolysed to a major V29-kDa fragment and minor bands
of approximately 35, 19 and 12 kDa (Fig. 5). The full-length
PS2 was entirely degraded. Using lower amounts of caspase-8,
the V29-, V19- and V12-kDa products gradually disap-
peared but the V35-kDa fragments showed up more clearly.
The latter picture was also observed when the highest concen-
tration of caspase-3 or -1 (60 ng p20 per 25 Wl) was used. In
mammalian cells, the alternative PS2 cleavage fragments mi-
grate on SDS-PAGE like molecules of V34 and V20 kDa
[14]. In conclusion, caspase-8, -3, -1, -6 and -7 (in decreasing
order of activity) proteolysed PS2 at the same site(s). Caspase-
11 and -2 exhibited no proteolytic activity on PS2.
Loetscher et al. [15] demonstrated by N-terminal sequenc-
ing that apoptosis-related cleavage of ectopically overex-
pressed murine and human PS2 took place at a cleavage rec-
ognition site D326SYD329 enclosing two di¡erent Asp residues.
In order to show that this site is actually cleaved by caspases,
we constructed a PS2 mutant protein (PS2M) where
D326SYD329 was substituted for G326SYA329. Then the casp-
ases displaying clear proteolytic activity on PS2 were incu-
bated with wt PS2 or PS2M. Fig. 6 demonstrates that
PS2M was not processed by any caspase. This indicates that
all proteolytic fragments derived from full-length PS2 are the
result of cleavage at the D326SYD329 sequence and that this
site is the major caspase target site. Note that the appearance
of the 29-kDa band of wt PS2 cannot be explained by poten-
tial additional caspase cleavage sites (Fig. 7). Presumably, this
band is a result of aggregation of hydrophobic domains [31].
However, when caspase-6 or -8 were incubated with PS2, an
extra V46-kDa band was observed (Figs. 5 and 6). This band
is reminiscent of the faint 44-kDa PS1 band obtained with
caspase-6 or caspase-8 and is of unknown origin.
3.3. PS1 mutations have no direct e¡ect on PS1 proteolysis by
caspases
We tested in vitro whether missense mutations in PS1, ob-
served in AD cases, altered the sensitivity to caspases. In
order to allow potential, subtle structural changes of the
PS1 mutants, translation was performed in the presence of
canine microsomal membranes. The latter technique was
used previously to determine the transmembrane domain
structure of PS1 [33]. The PS1 mutants Y115C, I143F,
I143T, E318G and G384A [34,35] were equally well trans-
lated; centrifugation was applied to con¢rm incorporation
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Fig. 6. In vitro cleavage of the PS2 caspase cleavage site mutant.
PS2 was mutated at one potential caspase cleavage site
(D326SYD329) to generate PS2M. Both PS2M (M) and wt PS2 (W)
were incubated under standard conditions with di¡erent caspases.
Symbols, see Fig. 5.
Fig. 7. Schematic representation of PS2, PS2M and the predicted
cleavage products.
Fig. 8. PS1 missense mutations do not a¡ect PS1 cleavage by casp-
ases. PS1 mutants and wt PS1 were in vitro transcribed and trans-
lated in rabbit reticulocyte lysates in the presence of canine microso-
mal membranes. Incorporation of PS1 proteins into the membranes
was con¢rmed by centrifugation. Wt or mutant PS1 proteins were
incubated with 60 ng of p20 subunit of caspase-3 (A) or caspase-8
(B) in a total volume of 25 Wl of caspase activation bu¡er for 1.5 h
at 37‡C. The resulting cleavage products (open arrowheads) were
separated on 12.5% SDS-PAGE and visualized by autoradiography.
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of the PS1 proteins into the membranes (data not shown).
Both caspase-3 and caspase-8 were chosen as the enzymatic
source, since the latter cleaved wt PS1 most e⁄ciently at either
one of the two cleavage sites (Fig. 1). Fig. 8 indicates that
none of the tested PS1 mutants exhibited a di¡erent proteo-
lytic sensitivity to the enzymatic activity of caspase-8 or cas-
pase-3. Also at limiting enzyme concentrations caspase-de-
pendent cleavage was not increased (data not shown). These
in vitro data demonstrate that the ¢ve AD mutations did not
in£uence the sensitivity of PS1 to caspase-dependent proteol-
ysis. It should be noted that incorporation of wt PS1 into
membranes (Fig. 8) did not change the accessibility of the
caspase cleavage sites as compared to non-incorporated PS1
(Fig. 1).
4. Discussion
The physiological relevance of caspase-mediated PS1/PS2
cleavage has already been suggested by staurosporine and
etoposide-induced apoptosis of H4 neuroglioma cells [14].
However, it was not clear which members of the caspase fam-
ily were capable of performing this alternative PS1/PS2 proc-
essing. This report focuses on alternative proteolysis of PS1
and PS2 using recombinant murine caspases and in vitro
translated human PS1/PS2. Human and murine PS1/PS2
have a very high degree of similarity, viz. 94%. The AQRD341
and D326SYD329 cleavage sites are conserved between man
and mouse in PS1 and PS2, respectively. However, the
ENDD329G site in human PS1 is changed to a GNDD329G
site in murine PS1. Nevertheless, overexpression of human
PS1 and human PS2 in mouse Neuro2a cells [15] or in human
H4 neuroglioma cells [14] resulted in identical apoptosis-re-
lated cleavage products in both cell lines, indicating that iden-
tical proteolysis occurred. Moreover, overexpression of hu-
man or murine PS2 in hamster BHK21 cells also resulted in
the same cleavage patterns [15].
We demonstrated that puri¢ed caspases are able to exert
proteolytic activity in vitro both on PS1 and PS2. Moreover,
we were able to con¢rm the cleavage sites AQRD341 for PS1
and D326SYD329 for PS2 [15] as actual caspase cleavage sites.
For PS1 a second caspase cleavage site ENDD329 was identi-
¢ed, which lies 12 amino acids N-terminally from AQRD341.
The existence of this proteolytic site has also been demon-
strated in vivo by Steiner et al. [36]. Remarkably, based on
the preference of caspases for a particular cleavage site in PS1,
the caspases could be divided in two groups. One group, con-
sisting of caspase-8, -6 and -11, predominantly used (in de-
creasing order of proteolytic e⁄ciency) the ENDD329 cleavage
site. When this site was removed by mutagenesis, these casp-
ases still recognized the AQRD341 site. The second group,
comprising caspase-3, -7 and -1, proteolysed (in decreasing
order of importance) the AQRD341 site but not the ENND329
site. In native cell lines and in brains, little or no full-length
PS1 is detected. In these cells PS1 undergoes a highly regu-
lated processing at or near M294 by unknown endoproteases,
which results in the generation of two stable fragments re-
ferred to as PS1-NTF and PS1-CTF [11,12]. PS1-NTF was
no substrate for caspase-8 and -3, whereas PS1-CTF was
clearly cleaved by caspase-8 and -3. This demonstrates that
not only the full-length PS1 gene product but also PS1-CTF is
a direct substrate for caspases and strengthens the physiolog-
ical relevance of caspase-mediated cleavage of PS1. The sit-
uation for PS2 is less complex than for PS1. Caspase-8 as well
as caspase-3, -1, -6 and -7 proteolysed, in decreasing order of
e⁄ciency, PS2 at the cleavage site D326SYD329 [15]. Caspase-2
and -11 were not active on PS2.
It was previously reported that only caspase-3 is important
for PS2 cleavage and that none of the caspases hydrolyze PS1
[20]. However, our data do not point in that direction, since
not only PS2 but also PS1 was a substrate for multiple casp-
ases. Our observations are in agreement with various reports
on alternative cleavage of PS2 as well as of PS1 obtained in
cultured cells and brain homogenates [14,15,37^39]. Our data
on PS1 cleavage are also strengthened by the fact that the PS1
cleavage site identi¢ed in cultured cells (AQRD341) is indeed a
target for caspases [15] and that conventional PS1-CTF is
directly recognized by caspases (Fig. 4). Peptide studies pre-
dicted that also proteases other than caspase-3 are involved in
PS1 and PS2 cleavage by brain homogenates [15]. In agree-
ment with this observation, we demonstrate that both casp-
ase-8 and caspase-3 cleave PS1 and PS2, as well as several
other caspases.
Although highly speculative, even the weak cleavage of
PS1/PS2 by caspase-1 can be physiologically important. In
the course of neuronal di¡erentiation of nerve growth fac-
tor-treated PC12 cells, a gradual enhancement of alternative
PS1 cleavage, resulting in 36-kDa and 14-kDa fragments, was
detected [37]. Since nerve growth factor rather prevents PC12
cells from dying, one may reason that proteases other than
caspases may be implicated in this alternative PS1 cleavage. It
is known that treatment of PC12 cells with nerve growth
factor also induces mature interleukin-1L secretion [40], sug-
gesting that caspase-1 is operating in these cells. Conse-
quently, sustained action of less e⁄ciently PS1-cleaving casp-
ases, such as proin£ammatory and highly inducible caspase-1,
might be responsible for the alternative PS1 cleavage in di¡er-
entiating PC12 cells. But proteolysis by unknown proteases
cannot be excluded.
Five PS1 mutations found in AD cases, viz. Y115C, I143F,
I143T, E318G and G384A, did not in£uence the sensitivity of
PS1 to caspase activity in vitro, providing evidence that PS1
missense mutations do not result in AD pathogenesis because
of altered caspase cleavage. This is in contrast to huntingtin,
the protein mutated in Huntington’s chorea, another neuro-
degenerative disease of the central nervous system [41]. Hun-
tingtin becomes a more e⁄cient substrate for caspases when a
polyglutamine tract is extended [42].
In conclusion, both PS1 and PS2 are directly cleaved by
multiple members of the caspase family, particularly casp-
ase-8 and -3. PS1 has two caspase cleavage sites, whereas
PS2 has only one. Although the biological relevance of casp-
ase-mediated PS1 cleavage is strengthened by the fact that
PS1-CTF is also a direct substrate for caspases, the patholog-
ical role of PS1 missense mutations in AD is unlikely to be
explained by an enhanced susceptibility to caspase-mediated
cleavage.
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